Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2024 Earnings Results

Crinetics Pharmaceuticals Misses on EPS — Stock Down 2.89%

Crinetics Pharmaceuticals reported a wider-than-expected loss per share, which contributed to a 2.89% drop in stock price. The lack of revenue figures and guidance may have left investors uncertain about the company's future performance. Overall, the cautious tone from management suggests that challenges may persist in the near term.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.93	N/A	-10.85%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Overall, management expressed caution regarding future performance. They highlighted ongoing challenges but did not provide specific metrics to address investor concerns.

Management did not provide specific revenue figures or guidance for the upcoming quarters.

The company acknowledged challenges in the current market environment.

Crinetics Pharmaceuticals Misses on EPS — Stock Down 2.89%

Key numbers

Management commentary

Crinetics Pharmaceuticals, Inc.

More earnings this week

Crinetics Pharmaceuticals Misses on EPS — Stock Down 2.89%

Key numbers

Management commentary